NCT04679415View on ClinicalTrials.gov

Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

December 17, 2020

Primary Completion Date

August 19, 2021

Study Completion Date

August 19, 2021

Conditions
COVID-19
Interventions
DRUG

hzVSF-v13

Dosage form: hzVSF-v13 40 mg/mL in a 5 mL vial Frequency: Dose at Day 1, 3, 7

DRUG

Placebo (Normal saline solution)

Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1, 3, 7

Trial Locations (3)

12120

Rumah Sakit Pusat Pertamina (include RSPP Extension Simprug), Jakarta

12550

Rumah Sakit Pasar Minggu, Jakarta

13230

Rumah Sakit Umum Persahabatan, Jakarta

Sponsors

Lead Sponsor

ImmuneMed, Inc.
All Listed Sponsors
lead

ImmuneMed, Inc.

INDUSTRY

NCT04679415 - Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia | Biotech Hunter | Biotech Hunter